Literature DB >> 30302212

Are FLT3 inhibitors likely to improve FLT3-mutated acute myeloid leukemia in the foreseeable future?

Sabine Kayser1,2,1,2, Mark J Levis3,3.   

Abstract

Entities:  

Keywords:  AML; FTL3 mutations; genetics; leukemia; novel therapy

Year:  2017        PMID： 30302212      PMCID： PMC6171975          DOI： 10.2217/ijh-2017-0001

Source DB:  PubMed          Journal:  Int J Hematol Oncol        ISSN： 2045-1393


× No keyword cloud information.
  11 in total

1.  Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.

Authors:  Richard F Schlenk; Sabine Kayser; Lars Bullinger; Guido Kobbe; Jochen Casper; Mark Ringhoffer; Gerhard Held; Peter Brossart; Michael Lübbert; Helmut R Salih; Thomas Kindler; Heinz A Horst; Gerald Wulf; David Nachbaur; Katharina Götze; Alexander Lamparter; Peter Paschka; Verena I Gaidzik; Veronica Teleanu; Daniela Späth; Axel Benner; Jürgen Krauter; Arnold Ganser; Hartmut Döhner; Konstanze Döhner
Journal:  Blood       Date:  2014-09-30       Impact factor: 22.113

Review 2.  Targeting FLT3 to treat leukemia.

Authors:  Heiko Konig; Mark Levis
Journal:  Expert Opin Ther Targets       Date:  2014-09-18       Impact factor: 6.902

Review 3.  FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?

Authors:  Mark Levis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

4.  Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.

Authors:  Christian H Brandts; Bülent Sargin; Miriam Rode; Christoph Biermann; Beate Lindtner; Joachim Schwäble; Horst Buerger; Carsten Müller-Tidow; Chunaram Choudhary; Martin McMahon; Wolfgang E Berdel; Hubert Serve
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

5.  Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.

Authors:  Farhad Ravandi; Mona Lisa Alattar; Michael R Grunwald; Michelle A Rudek; Trivikram Rajkhowa; Mary Ann Richie; Sherry Pierce; Naval Daver; Guillermo Garcia-Manero; Stefan Faderl; Aziz Nazha; Marina Konopleva; Gautam Borthakur; Jan Burger; Tapan Kadia; Sara Dellasala; Michael Andreeff; Jorge Cortes; Hagop Kantarjian; Mark Levis
Journal:  Blood       Date:  2013-04-23       Impact factor: 22.113

6.  Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.

Authors:  Marta Pratcorona; Salut Brunet; Josep Nomdedéu; Josep Maria Ribera; Mar Tormo; Rafael Duarte; Lourdes Escoda; Ramon Guàrdia; M Paz Queipo de Llano; Olga Salamero; Joan Bargay; Carmen Pedro; Josep Maria Martí; Montserrat Torrebadell; Marina Díaz-Beyá; Mireia Camós; Dolors Colomer; Montserrat Hoyos; Jorge Sierra; Jordi Esteve
Journal:  Blood       Date:  2013-02-01       Impact factor: 22.113

7.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

Authors:  Timothy J Ley; Christopher Miller; Li Ding; Benjamin J Raphael; Andrew J Mungall; A Gordon Robertson; Katherine Hoadley; Timothy J Triche; Peter W Laird; Jack D Baty; Lucinda L Fulton; Robert Fulton; Sharon E Heath; Joelle Kalicki-Veizer; Cyriac Kandoth; Jeffery M Klco; Daniel C Koboldt; Krishna-Latha Kanchi; Shashikant Kulkarni; Tamara L Lamprecht; David E Larson; Ling Lin; Charles Lu; Michael D McLellan; Joshua F McMichael; Jacqueline Payton; Heather Schmidt; David H Spencer; Michael H Tomasson; John W Wallis; Lukas D Wartman; Mark A Watson; John Welch; Michael C Wendl; Adrian Ally; Miruna Balasundaram; Inanc Birol; Yaron Butterfield; Readman Chiu; Andy Chu; Eric Chuah; Hye-Jung Chun; Richard Corbett; Noreen Dhalla; Ranabir Guin; An He; Carrie Hirst; Martin Hirst; Robert A Holt; Steven Jones; Aly Karsan; Darlene Lee; Haiyan I Li; Marco A Marra; Michael Mayo; Richard A Moore; Karen Mungall; Jeremy Parker; Erin Pleasance; Patrick Plettner; Jacquie Schein; Dominik Stoll; Lucas Swanson; Angela Tam; Nina Thiessen; Richard Varhol; Natasja Wye; Yongjun Zhao; Stacey Gabriel; Gad Getz; Carrie Sougnez; Lihua Zou; Mark D M Leiserson; Fabio Vandin; Hsin-Ta Wu; Frederick Applebaum; Stephen B Baylin; Rehan Akbani; Bradley M Broom; Ken Chen; Thomas C Motter; Khanh Nguyen; John N Weinstein; Nianziang Zhang; Martin L Ferguson; Christopher Adams; Aaron Black; Jay Bowen; Julie Gastier-Foster; Thomas Grossman; Tara Lichtenberg; Lisa Wise; Tanja Davidsen; John A Demchok; Kenna R Mills Shaw; Margi Sheth; Heidi J Sofia; Liming Yang; James R Downing; Greg Eley
Journal:  N Engl J Med       Date:  2013-05-01       Impact factor: 91.245

Review 8.  FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations.

Authors:  Sabine Kayser; Mark J Levis
Journal:  Leuk Lymphoma       Date:  2013-06-05

9.  Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.

Authors:  Allison Galanis; Hayley Ma; Trivikram Rajkhowa; Abhijit Ramachandran; Donald Small; Jorge Cortes; Mark Levis
Journal:  Blood       Date:  2013-11-13       Impact factor: 22.113

10.  Assessment of Minimal Residual Disease in Standard-Risk AML.

Authors:  Adam Ivey; Robert K Hills; Michael A Simpson; Jelena V Jovanovic; Amanda Gilkes; Angela Grech; Yashma Patel; Neesa Bhudia; Hassan Farah; Joanne Mason; Kerry Wall; Susanna Akiki; Michael Griffiths; Ellen Solomon; Frank McCaughan; David C Linch; Rosemary E Gale; Paresh Vyas; Sylvie D Freeman; Nigel Russell; Alan K Burnett; David Grimwade
Journal:  N Engl J Med       Date:  2016-01-20       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.